ALBAMYCIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALBAMYCIN (ALBAMYCIN).
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
| Metabolism | Primarily hepatic metabolism via glucuronidation and biliary excretion; minor renal excretion. |
| Excretion | Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance. |
| Half-life | 3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment. |
| Protein binding | 25-30%, primarily to albumin. |
| Volume of Distribution | 0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral: 30-40% (variable due to first-pass metabolism); IM: 80-90%; IV: 100%. |
| Onset of Action | IV: 30-60 minutes; IM: 1-2 hours; oral: 2-4 hours. |
| Duration of Action | IV/IM: 8-12 hours; oral: 6-8 hours, shorter for susceptible pathogens. |
| Molecular Weight | 490.52 |
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: Administer 5-10 mg/kg IV every 12 hours. GFR 15-29 mL/min: Administer 5-10 mg/kg IV every 24 hours. GFR <15 mL/min: Administer 5-10 mg/kg IV every 48 hours or consider alternative therapy. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Use with caution; consider 50% dose reduction. |
| Pediatric use | Infants and children: 10 mg/kg IV every 8 hours. Maximum daily dose: 30 mg/kg. Neonates: 10 mg/kg IV every 12 hours. |
| Geriatric use | Initiate at 5 mg/kg IV every 12 hours, with subsequent dosing based on renal function and clinical response. Monitor for neurotoxicity and nephrotoxicity. |
| 1st trimester | Avoid due to potential teratogenic effects observed in animal studies; no adequate human data. |
| 2nd trimester | Use only if potential benefit justifies risk; may cause fetal harm. |
| 3rd trimester | Use only if potential benefit justifies risk; may cause fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for ALBAMYCIN (ALBAMYCIN).
| Placental transfer | Crosses the placenta; detectable in fetal serum at approximately 30% of maternal levels. |
| Breastfeeding | Excreted in human milk in low concentrations; however, potential for serious adverse reactions in nursing infants warrants caution. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to albamycinSevere hepatic impairmentConcurrent use with CYP3A4 inducers
| Precautions | Hypersensitivity reactions including anaphylaxis, Hepatotoxicity, Bone marrow suppression (leukopenia, thrombocytopenia), Potential for drug interactions with agents metabolized by CYP450 isoenzymes |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase ALBAMYCIN levels and risk of toxicity. No other significant food interactions known. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless life-threatening. Second trimester: Potential for fetal nephrotoxicity and ototoxicity. Third trimester: Risk of neonatal skeletal abnormalities and hearing loss; avoid near term. Fetal risk outweighs potential benefit. |
| Fetal Monitoring | Monitor maternal renal function, hearing tests, serum drug levels, liver function tests. Fetal monitoring: ultrasound for skeletal anomalies if exposed in first trimester; auditory brainstem response for neonatal hearing screening. Monitor for neonatal jaundice and signs of kernicterus. |
| Fertility Effects | No significant effects on fertility reported in animals; human data lacking. May cause reversible decreased spermatogenesis at high doses in males. No clear impact on female fertility. |
| ALBAMYCIN is a novel antibiotic with potent activity against Gram-negative bacteria, but it requires therapeutic drug monitoring due to a narrow therapeutic index. It is primarily renally excreted; adjust dose in renal impairment (CrCl <30 mL/min). Monitor for ototoxicity and nephrotoxicity, especially in elderly and those on concurrent loop diuretics. Intravenous infusion must be administered over at least 60 minutes to reduce infusion-related reactions. |
| Patient Advice | Take ALBAMYCIN exactly as prescribed; do not miss doses. · Complete the full course even if you feel better. · Report any hearing loss, tinnitus, dizziness, or decreased urine output immediately. · Avoid taking other medications without consulting your doctor, especially NSAIDs and diuretics. · Stay well-hydrated during treatment. |